Marta Mikulak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marta Mikulak has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Katarzyna Wojciechowska-Durczynska
Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, Poland
2 shared publications - Andrzej Lewiński
Department of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital – Research Institute, Lodz, Poland
1 shared publication - Arkadiusz Zygmunt
Department of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital—Research Institute, 93-338 Lodz, Poland
1 shared publication - Ewa Bieniek
Faculty of Medicine—Collegium Medicum, Department of Internal Medicine, Endocrinology & Diabetes, Mazovian University in Plock, Dąbrowskiego 2, 09-402 Plock, Poland
1 shared publication - Kinga Krawczyk-Rusiecka
Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland
1 shared publication - Krzysztof Cezary Lewandowski
Faculty of Medicine—Collegium Medicum, Department of Internal Medicine, Endocrinology & Diabetes, Mazovian University in Plock, Dąbrowskiego 2, 09-402 Plock, Poland
1 shared publication
Latest Publications
- Open Access
- 7 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4410
Effect of a Prior Two-Hour Postural Test on Seated Saline Suppression Test Results in Patients Predominantly Evaluated for Adrenal Incidentalomas
Background/Objectives: The Seated Saline Suppression Test (SSST) is widely used for investigation of primary hyperaldosteronism (PA); however, the impact of a one-hour sitting period prior to SSST (as recommended by the Endocrine Society, with a 7.8 ng/dL aldosterone cut-off) on the test outcome remains unclear. Methods: In 82 individuals (23 males) aged 57.3 ± 12.6 years, BMI 27.1 ± 5.1 kg/m2, where the majority were diagnosed with adrenal incidentalomas (n = 75), we performed an SSST preceded by a 120 min postural test (first protocol), or immediately after waking (second protocol, a cross-over design). Results: Though aldosterone and renin concentrations before the onset of SSST were higher after the first protocol (p < 0.001), an overall suppression of aldosterone was not different after the first versus the second protocol (6.34 ± 0.68 ng/dL (mean ± SEM) versus 5.74 ± 0.66 ng/dL, p = 0.124). There was no significant difference between the number of individuals with aldosterone > 10 ng/dL, i.e., nine (11%) for the first protocol versus eight (9.75%) for the second protocol, p = 1.00, and for the “grey zone” aldosterone of 7.8–10 ng/mL after SSST (five (6.1%) in each group, p = 1.0). Aldosterone-to-direct-renin ratio (ADR ratio) was higher in those who failed to suppress aldosterone (p < 0.001) but offered a poor prediction of SSST outcome with the lowest ADR ratio of 0.398 ng/dL/µIU/mL in those with aldosterone > 7.8 ng/dL, and the highest ADR ratio of 26.04 ng/dL/µIU/mL for those with aldosterone < 7.8 ng/dL on SSST. Conclusions: Two-hour postural test before SSST does not significantly impact aldosterone suppression after saline infusion, while the ADR ratio does not fully discriminate between those who suppress and those who do not suppress aldosterone secretion on SSST, at least in those with adrenal incidentalomas.
- 7 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4410
Open AccessEffect of a Prior Two-Hour Postural Test on Seated Saline Suppression Test Results in Patients Predominantly Evaluated for Adrenal Incidentalomas
Background/Objectives: The Seated Saline Suppression Test (SSST) is widely used for investigation of primary hyperaldosteronism (PA); however, the impact of a one-hour sitting period prior to SSST (as recommended by the Endocrine Society, with a 7.8 ng/dL aldosterone cut-off) on the test outcome remains unclear. Methods: In 82 individuals (23 males) aged 57.3 ± 12.6 years, BMI 27.1 ± 5.1 kg/m2, where the majority were diagnosed with adrenal incidentalomas (n = 75), we performed an SSST preceded by a 120 min postural test (first protocol), or immediately after waking (second protocol, a cross-over design). Results: Though aldosterone and renin concentrations before the onset of SSST were higher after the first protocol (p < 0.001), an overall suppression of aldosterone was not different after the first versus the second protocol (6.34 ± 0.68 ng/dL (mean ± SEM) versus 5.74 ± 0.66 ng/dL, p = 0.124). There was no significant difference between the number of individuals with aldosterone > 10 ng/dL, i.e., nine (11%) for the first protocol versus eight (9.75%) for the second protocol, p = 1.00, and for the “grey zone” aldosterone of 7.8–10 ng/mL after SSST (five (6.1%) in each group, p = 1.0). Aldosterone-to-direct-renin ratio (ADR ratio) was higher in those who failed to suppress aldosterone (p < 0.001) but offered a poor prediction of SSST outcome with the lowest ADR ratio of 0.398 ng/dL/µIU/mL in those with aldosterone > 7.8 ng/dL, and the highest ADR ratio of 26.04 ng/dL/µIU/mL for those with aldosterone < 7.8 ng/dL on SSST. Conclusions: Two-hour postural test before SSST does not significantly impact aldosterone suppression after saline infusion, while the ADR ratio does not fully discriminate between those who suppress and those who do not suppress aldosterone secretion on SSST, at least in those with adrenal incidentalomas.
- Open Access
- 16 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (18) , 11692
Difficult Therapeutic Decisions in Gorham-Stout Disease–Case Report and Review of the Literature
Gorham-Stout disease (GSD) is a very rare, life-threatening condition characterized by the proliferation of lymphatic vessels and osteolysis. Unfortunately, no standard treatment has been determined for management of GSD. The available therapies are not equally effective and carry substantial side-effects. We report a 42-year-old female with GSD manifested in multifocal osteolysis and chronic chylothorax and ascites. The combined treatment with sirolimus and zoledronic acid due to its synergism of action was introduced. To our knowledge, this is the first Polish case report of adult patients with Gorham-Stout disease.
- 16 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (18) , 11692
Open AccessDifficult Therapeutic Decisions in Gorham-Stout Disease–Case Report and Review of the Literature
Gorham-Stout disease (GSD) is a very rare, life-threatening condition characterized by the proliferation of lymphatic vessels and osteolysis. Unfortunately, no standard treatment has been determined for management of GSD. The available therapies are not equally effective and carry substantial side-effects. We report a 42-year-old female with GSD manifested in multifocal osteolysis and chronic chylothorax and ascites. The combined treatment with sirolimus and zoledronic acid due to its synergism of action was introduced. To our knowledge, this is the first Polish case report of adult patients with Gorham-Stout disease.